| |
Phase 3 Efuxifermin Fatty Liver/MASH Trial Ongoing; EASL 96 weeks HARMONY phase 2b study Results
|
| |
| |
EFX has been engineered to mimic the biological activity of fibroblast growth factor 21 (FGF21), which regulates multiple metabolic pathways and cellular processes. By delivering sustained and balanced signaling through FGF21's receptors in liver and adipose tissue, EFX has the potential to treat MASH by addressing all core drivers of disease progression.
https://akerotx.com/efruxifermin/
The Phase 3 SYNCHRONY clinical trial program consists of three trials, two of which have started enrolling patients and the third to be initiated in Q2'24. The first two trials under way are parallel, randomized, placebo-controlled trials: SYNCHRONY Histology evaluating the efficacy and safety of EFX in patients with biopsy-confirmed pre-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH), and SYNCHRONY Real-World assessing safety and tolerability of EFX in patients with non-invasively diagnosed MASH or metabolic dysfunction-associated steatotic liver disease (MASLD).
Read more at Clinicaltrials.gov:
SYNCHRONY Histology and
SYNCHRONY Real-World.
https://akerotx.com/clinical-trials/
Expanded Access Program
| |
| |
| |
|
|
|
